A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Saved in:
| Title: | A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. |
|---|---|
| Authors: | Filho OM; Dana-Farber Cancer Institute, Boston, MA, USA. ometzger@partners.org.; Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02468, USA. ometzger@partners.org., Giobbie-Hurder A; Dana-Farber Cancer Institute, Boston, MA, USA., Lin NU; Dana-Farber Cancer Institute, Boston, MA, USA., Faggen M; Dana-Farber Cancer Institute, Boston, MA, USA., Come S; Beth Israel Deaconess Medical Center, Boston, MA, USA., Openshaw T; Eastern Maine Medical Center, Bangor, ME, USA., Constantine M; Dana-Farber Cancer Institute, Boston, MA, USA., Walsh J; Dana-Farber Cancer Institute, Boston, MA, USA., Freedman RA; Dana-Farber Cancer Institute, Boston, MA, USA., Schneider B; Simon Cancer Center at Indiana University, Indianapolis, IN, USA., Burstein HJ; Dana-Farber Cancer Institute, Boston, MA, USA., Mayer EL |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jan; Vol. 185 (1), pp. 135-144. Date of Electronic Publication: 2020 Oct 06. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-020-05928-4 |
